What this study is
The objectives of this study are to characterize MPS VII disease presentation and progression and assess long-term effectiveness and safety, including hypersensitivity reactions and immunogenicity of vestronidase alfa.
What's being tested
- No Intervention
Intervention · OTHER
Access to any treatment is through authorized commercial use or available expanded access programs only and not as a part of this DMP.
Study details
- Official title
- Mucopolysaccharidosis VII Disease Monitoring Program (MPS VII DMP)
- Sponsor
- Ultragenyx Pharmaceutical Inc
- Conditions
- Mucopolysaccharidosis VII · MPS VII · MPS 7 · Sly Syndrome
- Enrolling
- 50 people
- Starts
- 2018-01-29
- Est. completion
- 2032-04
- Record
- View on ClinicalTrials.gov ↗
Who can join
Sex ALLHealthy volunteers Not acceptedYou may qualify if
- Diagnosis of MPS VII based on laboratory diagnosis, including either enzymatic or mutation analysis.
- Willing and able to provide written informed consent or, in the case of patients under the age of 18 (or below adult ages as defined by local laws and regulations) or patients >18 years of age who have cognitive deficiencies, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the DMP has been explained, and prior to any research-related procedures.
- Willing to comply with DMP visit schedule.
You can't join if
- Concurrent participation in other pharmaceutical company-sponsored interventional clinical trial unless approved by Ultragenyx.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (14)
12 openChildren's Hospital of Orange County
Orange, California, United States
RecruitingChildren's National Health System
Washington D.C., District of Columbia, United States
RecruitingAnn & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
RecruitingUniversity of Michigan
Ann Arbor, Michigan, United States
RecruitingUniversity of Utah Medical Center
Salt Lake City, Utah, United States
RecruitingSeattle Children's Hospital
Seattle, Washington, United States
RecruitingNew York University Langone Medical Center
New York, New York, United States
Terminated
7 sites outside the US
Laboratorio de Neuroquimica Dr. N.A. Chamoles S.R.L.
Buenos Aires, Buenos Aires, Argentina
RecruitingHospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
RecruitingCentre Hospitalier Universitaire La Timone
Marseille, Provence-Alpes-Côte d'Azur Region, France
RecruitingUniversitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Germany
RecruitingCentro Hospitalar do Porto
Porto, Portugal
RecruitingHospital Universitario Virgen del Rocío Pabellón Infantil
Seville, Sevilla, Spain
RecruitingErasmus University Medical Center Rotterdam
Rotterdam, South Holland, Netherlands
Terminated
Study team
Sponsor
Ultragenyx Pharmaceutical Inc
Study ID UX003-CL401
Study director
Medical Director
Ultragenyx Pharmaceuticals Inc.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.